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During cerebellum development, Sonic hedgehog (Shh)-induced proliferation of cerebellar granular neuronal precursors
(CGNPs) is potently inhibited by bone morphogenetic proteins (BMPs). We have previously reported the upregulation of
TIEG-1 andMash1, two antimitotic factors that modulateMYCN transcription and N-Myc activity, in response to BMP2. To
gain further insight into the BMP antimitotic mechanism, we used microRNA (miRNA) arrays to compare the miRNAs of
CGNPs proliferating in response to Shh with those of CGNPs treated with Shh plus BMP2. The array analysis revealed that
miRNA 11 (miR-22) levels significantly increased in cells treated with BMP2. Additionally, in P7mouse cerebellum, miR-22 dis-
tributionmostly recapitulated the combination of BMP2 and BMP4 expression patterns. Accordingly, in CGNP cultures, miR-22
overexpression significantly reduced cell proliferation, whereas miR-22 suppression diminished BMP2 antiproliferative activity.
In contrast to BMP2, miR-22 did not induce neural differentiation but instead significantly increased cell cycle length. Consis-
tent with the central role played by N-myc on CGNP proliferation, Max was revealed as a direct target of miR-22, andmiR-22
expression caused a significant reduction of Max protein levels and N-myc/Max-dependent promoter activity. Therefore, we
conclude that, in addition to the previously described mechanisms, miR-22 plays a specific role on downstream BMPs through
cerebellum growth.
Cerebellar granular neuronal precursors (CGNPs) are gener-ated within the external germinal layer (EGL) during devel-
opment of the cerebellar cortex. Clonal expansion of CGNPs is
achieved by the mitogenic activity of Sonic hedgehog (Shh) sig-
naling emanating from the Purkinje cells (PC) to the EGL (1, 2).
During cerebellum development, CGNPs exit the cell cycle and
migrate through the Purkinje cells to establish the three layers of
the cerebellar cortex (3). MYCN is a direct Shh target (4) and one
of the main downstream effectors of the Shh pathway during the
expansion of CGNPs (4–6). The MYC transcription factors have
well-established roles in regulating cell cycle progression and cell
survival (7). MYC proteins belong to the basic helix-loop-helix
(bHLH) family of transcription factors. The mammalian MYC
family includes three different genes: Myc (C-MYC), encoding
Myc protein, which displays a universal distribution, MYCN, en-
coding N-myc, and MYCL, encoding L-myc proteins, the last two
being expressed mainly in the nervous system and the lungs, re-
spectively. Despite their different expression patterns, Myc and
N-myc proteins are mostly functionally interchangeable (8), al-
though Myc overexpression not only induced significantly more
aggressive tumors than N-myc in a murine model of medulloblas-
toma but also induced a completely different medulloblastoma
subgroup, group 3 (9).
N-myc forms heterodimers with Max to activate transcription
by binding to E-box motifs (CANNTG) (10, 11) of different genes
involved in cell cycle regulation such as cyclin D2 (12). Shh-de-
pendent proliferation of CGNPs depends entirely on N-myc ac-
tivity (4, 6). The existence of local signals that counteract the mi-
togenic effects of Shh was predicted by the fact that exit from the
cell cycle and migration of CGNPs both occur in a Shh-rich envi-
ronment. Bone morphogenetic proteins (BMPs) belong to the
transforming growth factor  (TGF-) family of growth factors
and play important roles during the development of the central
nervous system. BMP2 to -4 are expressed at the EGL during the
early genesis of postnatal cerebellum, where they function as pow-
erful inhibitors of Shh-mediated proliferation of CGNPs (13). In
CGNPs, BMP2 to -4 control MYCN activity through a multifac-
eted mechanism. On the one hand, BMPs induce the transcrip-
tional repressor TIEG-1, which inhibits the activity of the MYCN
promoter (14). On the other hand, BMPs potently enhance the
levels of the bHLH proneural protein Mash1; Mash1-E12 dimers
compete with N-myc/Max for the occupancy of the E boxes on
N-myc target genes (15). In addition, using a posttranscriptional
mechanism, BMPs raise the protein levels of Math1 (16), a pro-
neural transcription factor required for Shh-induced proliferation
of CGNPs and medulloblastoma formation (17, 18). microRNAs
(miRNAs) comprise a large family of small (21-nucleotide [nt])
noncoding RNAs that have emerged as key regulators of posttran-
scriptional gene expression in virtually all cellular events (19, 20).
miRNAs regulate protein synthesis by base pairing to target
mRNAs. In animals, the majority of known miRNAs form imper-
fect hybrids between the mRNA 3= untranslated region (3=UTR)
and the miRNA 5=-proximal “seed region” (positions 2 to 8) (21).
Ordinarily, miRNAs inhibit protein synthesis by repressing trans-
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lation and/or inducing deadenylation and subsequent degrada-
tion of their mRNA targets (21).
In the present work, we addressed whether the signals that
antagonize Shh-dependent proliferation are, at least in part, me-
diated by miRNA molecules. Using mouse miRNA arrays, we
compared the miRNA population from CGNPs proliferating un-
der the influence of Shh with the miRNAs of CGNPs treated with
Shh plus BMP2 or dibutyryl-cyclic AMP (DBA), a PKA activator
that inhibits proliferation (14, 15). The array analysis revealed that
miRNA 11 (miR-22) levels increased significantly after treatment
with either DBA or BMP2. Likewise, the ectopic expression of
miR-22 had a potent antiproliferative effect, significantly increas-
ing the cell cycle duration in CGNPs. In addition, we observed that
in P7 mouse cerebellum, the expression pattern of miR-22 reca-
pitulated mostly BMP2 plus BMP4 expression patterns and that
the suppression of miR-22 activity significantly reduced the anti-
proliferative effect of BMP2 on CGNPs. Interestingly, Max, which
forms heterodimers with N-Myc, was scored as one of the best
targets of miR-22 using three different target scan programs. In
agreement, the expression of miR-22 not only decreased Max pro-
tein levels but also significantly reduced N-Myc/Max-dependent
promoter activity. Consequently, miR-22 expression selectively
reduced the proliferation of Shh/N-myc-dependent neural tumor
cell lines. Therefore, we conclude that miR-22 acts downstream
from BMPs to modulate the activity of N-myc in CGNPs during
the development of cerebellum.
MATERIALS AND METHODS
Antibodies and chemicals. (i) Mouse monoclonal antibodies. The fol-
lowing mouse monoclonal antibodies were procured: anti-PCNA (SC-56;
Santa Cruz), anticalbindin (CB-955; Sigma), anti-HuC/D (A21271; Mo-
lecular Probes), anti--tubulin III/Tuj1 (MMS435P; Covance), anti-Ki67
(16667; Abcam), and anti--actin (AC15; Sigma).
(ii) Rat monoclonal antibodies. Anti-8-bromodeoxyuridine (anti-
BrdU) (BU1/75) was obtained from AbD-Serotec.
(iii) Rabbit polyclonal antibodies. Anti-green fluorescent protein
(anti-GFP) was produced in our laboratory, and the following were ob-
tained commercially: antiretinoblastoma phospho-Ser807 and Cdc2
phospho-Tyr15 (9308 and 9111; Cell Signaling), anti-Max (SC197; Santa
Cruz), anti-cleaved-caspase 3 (559565; BD), and anti-histone 3-phospho-
Ser10 (06-570; Millipore).
(iv) Immunocytochemical analysis. For immunocytochemical anal-
ysis, fluorochrome-conjugated secondary antibodies anti-rabbit anti-
body–Alexa Fluor 488 and anti-mouse antibody–Alexa Fluor 594 (Molec-
ular Probes) were used. Protein A/G-coupled peroxidase was obtained
from Pierce. Human BMP2 produced in CHO cells was from R&D. Shh
N-terminal peptide was produced in our laboratory as previously re-
ported (14). 8-Bromodeoxyuridine was purchased from Sigma. DBA was
purchased from Calbiochem.
Cell cultures and transfection. The preparation of cerebellar cultures
was performed using a modification of the Papain method as described
previously (13). For transient-transfection experiments, freshly isolated
cells were electroporated in suspension and plated in Neurobasal plus
B-27 medium (Invitrogen) supplemented with KCl (25 mM), glutamine
(1 mM), and Shh (3 g/ml) on poly-L-Lys- plus laminin-coated dishes.
Twenty-four hours later, the medium was replaced by fresh medium con-
taining the corresponding treatments, considering this moment as time
zero. Electroporation was performed using the Microporator MP-100
(Digital Bio, Seoul, South Korea) according to the manufacturer’s instruc-
tions, with a single pulse of 1,700 V for 20 milliseconds. Neuroblastoma
and medulloblastoma cell lines were grown on poly-L-Lys coated dishes in
Dulbecco’s modified Eagle medium (DMEM)–10% fetal bovine serum
(FBS) and DMEM–F-12–10% FBS, respectively.
DNAconstructs.The miRNA expression vector pMICRO was created
from pCIG, a GFP polycistronic expression vector, by the insertion of a
new multiple-cloning site between the GFP-coding region and the rabbit
-globin polyadenylation site. To generate miRNA expression constructs,
pre-miRNAs region, flanked by 200 additional nucleotides, were PCR-
amplified from murine genomic DNA and cloned into pMICRO expres-
sion vector. The expression efficiency of pMICRO was confirmed through
a real-time PCR that specifically detected the mature form of miR-22. A
miR-22 decoy construct (dec22) was created by adapting the directions
published in reference 22. Briefly, four repeats of a “bulged” (imperfectly
complementary) miR-22 sequence (ACAGTTCTTCATCGGCAGCTT)
separated by spacer sequences (CGAT) were cloned into pMICRO
polylinker, and the capacity of dec22 to neutralize miR-22 activity was
checked in HEK cells using the pLUCMAX construct. pLUCMAX vector
was created from pGL3 basic vector (Promega) to study the effect of
miR-22 expression onMAX 3=UTR. Briefly, using the pGL3 backbone (no
promoter), a simian virus 40 (SV40) promoter and the entireMAX 3=UTR
were cloned upstream and downstream, respectively, of the LUC gene.
pLUCMAX-Scr is a version of pLUCMAX in which the miR-22 binding
site on MAX 3=UTR (GGCAGCU, nucleotides 333 to 339 of mouse MAX
3= UTR) was scrambled by site-directed mutagenesis (UACCGCG). Sim-
ilarly, the miR-22 seed sequence (CCGUCGA) was scrambled (CGUC
GAC) and cloned into pMICRO to create Scr22 (scrambled miR-22).
Empty pMICRO and pMICRO expressing Scr22 were both used as trans-
fection controls.
The cyclin D2 promoter reporter plasmid containing the regions
1624 to 1 was obtained from Rene H. Medema (University Medical
Center Utrecht, Utrecht, Netherlands). The 5 E-box reporter promoter
was constructed within the pGL3 (Promega) plasmid and includes five
repetitions of the CACGTG motif and a minimal TATA box. The cyto-
megalovirus (CMV)-Renilla luciferase was purchased from Promega. To
generate a Max expression vector (pCIG-Max), the entire MAX coding
sequence was PCR amplified from human brain cortex cDNA and cloned
into pCIG.
BrdU incorporation assay and immunocytochemistry.For the BrdU
incorporation assay, cells were pulsed with 50 ng/ml of BrdU 6 h prior to
fixation with 4% paraformaldehyde. Cells were then permeabilized with
methanol for 5 min, washed twice with phosphate-buffered saline (PBS),
and incubated for 10 min with DNase I in DNase buffer (10 mM Tris-HCl
[pH 7.4], 2.5 mM MgCl2, 0.1 mM CaCl2). Finally, cells were washed once
with PBS, incubated overnight at 4°C with a mouse monoclonal anti-
BrdU antibody, and developed with anti-mouse antibody–Alexa Fluor
555.
Immunohistochemistry and in situ hybridization. Mouse cerebella
were fixed overnight with 4% paraformaldehyde, rinsed three times, and
embedded in agarose blocks (5% agarose, 10% sucrose). Sections (50M)
were obtained by vibratome. Exiqon miRCURY LNA double digoxigenin
(DIG) (5=-3=)-labeled probes of 22 nucleotides were used to perform in
situ hybridizations against miR-22. According to the manufacturer’s di-
rections, scrambled microRNA and miR-22 probes were used at 40 nM,
the U6 snRNA probe was used at 1 nM, and hybridization was done
overnight at 52°C. In situ hybridizations for MYCN were performed with
DIG-labeled riboprobes (500 nt) using standard protocols previously
published (13). Immunohistochemistry was realized using vibratome sec-
tions in “free-floating” conditions. The images were taken with a Leica
optical microscope for in situ hybridization and with a Leica TCS SP5
confocal microscope for immunohistochemistry.
Immunoprecipitation and immunoblotting. Cultures grown in
6-well dishes were lysed with radioimmunoprecipitation assay (RIPA)
buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate [DOC], 0.1% SDS,
50 mM Tris [pH 7.5], and 1 mM phenylmethylsulfonyl fluoride [PMSF])
72 h after electroporation. Following sonication, insoluble material was
removed by centrifugation, 1/10 of the resulting supernatant was reserved
as “input,” and the remaining part was immunoprecipitated overnight at
4°C with anti-Max rabbit polyclonal antibody. Antigen-antibody com-
miR-22 Regulates Cell Cycle Length
July 2013 Volume 33 Number 14 mcb.asm.org 2707
 o
n
 D
ecem
ber 12, 2013 by Red de Bibliotecas del CSIC
http://m
cb.asm
.org/
D
ow
nloaded from
 
plexes were collected with protein A-Sepharose beads (Amersham Biosci-
ences). Then, beads were washed three times with Tris-buffered saline (25
mM Tris, pH 7.5, 140 mM NaCl), boiled in 1 SDS Laemmli sample
buffer, resolved in 12% SDS-PAGE, transferred to nitrocellulose mem-
branes, blocked with 8% nonfat dry milk in TTBS (150 mM NaCl, 0.05%
Tween 20, and 20 mM Tris-HCl, pH 7.4), and then incubated with the
same anti-Max antibody. The “inputs” were separated in a parallel gel and
blotted with anti--actin monoclonal antibody. The blots were developed
using protein A/G-coupled peroxidase plus the enhanced chemolumines-
cence (ECL) system and captured with the Versadoc imaging system from
Bio-Rad. Expression values were quantified with Quantity One software
(Bio-Rad); values were actin normalized and referenced to Scr22 (scram-
bled miR-22)-transfected controls.
Luciferase assays. Luciferase reporter constructs (pLUCMAX, cy-
clin-D2 promoter, or 5 E-box) were coelectroporated with a CMV-
Renilla vector and a 3-fold excess of the indicated expression constructs.
Cells were cultured for 48 h and then lysed and analyzed with the
dual-luciferase reporter assay system (Promega) according to the
manufacturer’s instructions. Luciferase activity was detected with an
Orion II microplate luminometer (Berthold). Luciferase data were
normalized to the Renilla values, and results were plotted and ex-
pressed in arbitrary units as the means and standard deviations (SD) of
three different experiments.
Cell counting and statistical analysis. Cell counting was calculated as
the percentage of positive cells (BrdU, HuC/D, etc.) among the trans-
fected population (GFP-expressing cells). Duplicate wells from at least
three different cultures were counted (minimum, 6 wells). The number of
cells counted for each data point is indicated in the bars in the figures.
Quantitative data were expressed as the means  SD. Significant differ-
ences between groups were tested by one-way analysis of variance
(ANOVA) followed by Tukey’s multiple-comparison test (except in the
experiment shown in Fig. 2D, where a two-way ANOVA followed by a
Bonferroni posttest was applied).
RNA isolation, RT-PCR, and real-time PCR. Total RNA was isolated
from 10-cm culture plates using the miRVANA miRNA isolation kit ac-
cording to the manufacturer’s indications. To study MAX mRNA levels
by semiquantitative reverse transcription (RT)-PCR, total mRNA was
extracted using TRIzol reagent (Invitrogen). Real-time PCR analysis of
miRNAs was performed using the miRCURY microRNA PCR system
(Exiqon). Real-time PCR was performed in the MyiQ Single Color Real-
Time PCR Detection system (Bio-Rad).
Microarray preparation and statistical analysis. Agilent mouse
miRNA microarrays V2 (G4470B) were used to analyze independent sam-
ples (control, DBA-treated, and BMP-treated cells). Briefly, 500 ng of total
RNA from each sample was chemically labeled with cyanine 3-pCp using
the Agilent miRNA Complete labeling and hybridization kit (p/n5190-
0456). Labeled samples were dried and resuspended in nuclease-free wa-
ter and cohybridized with in situ hybridization buffer (Agilent) for 20 h at
55°C and washed at room temperature for 5 min in Gene Expression
Wash Buffer 1 (Agilent) and for 5 min at 37°C in Gene Expression Wash
Buffer 2 (Agilent). The images were generated on a confocal microarray
scanner (G2505B; Agilent) at 5-m resolution and quantified using Fea-
ture Extraction (Agilent). Extracted log2-transformed intensities were
quantile normalized to make all data comparable. To assess differential
expression, significance analysis of microarrays (SAM) was used. Results
of SAM analysis were corrected for multiple testing using the false-discov-
ery rate (FDR) method. Relevant probe significance cutoff was set as a
combination of a q-value below 5% and an absolute fold change above 1.2.
Final relative expression values were computed by taking the median log2
ratio of the respective probes for each miRNA.
RESULTS
miR-22 expression is induced by two independent antiprolif-
erative pathways in CGNPs. Shh-induced proliferation of
CGNPs can be reversed by growth factors such as basic fibroblast
growth factor (b-FGF) (2) and BMPs (13) or by direct activation
of cyclic AMP (cAMP)-dependent protein kinase A (PKA) with
either forskolin, which directly stimulates adenylate cyclase (AC)
(2), or the cAMP analogue DBA (13). Activation of the Shh path-
way promotes the translocation of active forms of Gli2-3 tran-
scription factors to the nucleus, which in turn stimulate the pro-
duction of other transcription factors, including Gli1 and N-myc
(4, 6). PKA inhibits the Shh pathway through phosphorylation-
dependent generation of the repressor forms of Gli2-3 transcrip-
tion factors (23), whereas the BMPs act through a PKA-indepen-
dent mechanism that requires downregulation ofMYCN function
(14). Therefore, to identify miRNAs participating in these path-
ways that modulate CGNP proliferation, we compared miRNA
levels in proliferating CGNPs (Shh, 3g/ml) with those of CGNPs
treated with 1 mM DBA or 100 ng/ml of BMP2 for 2 or 24 h (Fig.
1A). The heat map in Fig. 1B shows all the miRNA species that
varied significantly between control cultures and those treated for
24 h with DBA or BMP2 (fold change values are indicated on the
left of each heat map cell). Thus, BMP2 reduced the expression of
miRNAs 17*, 19b, and 18a and increased miR-22 only. Interest-
ingly, although the number of miRNAs regulated by DBA treat-
ment was greater than with BMP-2, all miRNAs regulated by
BMP-2 were also regulated similarly by DBA (Fig. 1B). Notably,
miR-22 was the miRNA most changed under these two treatment
conditions and was the only miRNA consistently upregulated by
the four experimental conditions tested (DBA or BMP2, 2 or 24 h
of treatment, heat map of 2-h treatment) (data not shown).
miR-22 is expressed in the cerebellar EGL. Although most of
the cell types found in the adult cerebellum proliferate only during
embryonic stages, more than 90% of the final cellular content of a
mouse cerebellum consists of granular cells generated during the
first 2 weeks of postnatal development. During this period, the
CGNPs proliferate extensively at the EGL and migrate to the in-
ternal granular layer (IGL). Despite the intense proliferation, the
thickness of the EGL remains nearly constant for more than 1
week, due to the balance between proliferation and migration pro-
cesses, causing though an enormous increase in IGL size. Given
our miRNA array results, we next confirmed the effect of DBA and
BPM2 treatments on miR-22 expression by quantitative real-time
PCR (Fig. 1C). In agreement with the array predictions, both
treatments significantly increased miR-22 levels in CGNP cultures
after 24 h, with BMP2 exerting a stronger effect than DBA. Previ-
ously, we reported that in P7 rat cerebellum, BMP2 and BMP4 are
expressed predominantly at the IGL and the inner EGL, respec-
tively (13). Thus, we next questioned whether the pattern of
miR-22 expression during normal cerebellum development was
related to BMP expression. So, we performed “in situ” hybridiza-
tions (IH) on sagittal sections of mouse cerebellum using a com-
mercial probe specifically designed against miR-22 (miRCURY
LNA). We observed that in P7 mouse cerebellum, miR-22 was
expressed at the inner EGL, at the Purkinje cells (PC), and espe-
cially at the IGL compared to the negative control (scrambled
miRNA probe). We used a commercial probe directed against U6
SnRNA (which labels all cells in cerebellum) as a positive control
and a riboprobe directed againstMYCN (which labels the external
EGL [4]) as a landmark (Fig. 1D). In addition, we observed that
miR-22 expression was restricted to the IGL in P21 mice and
barely detectable in the adult animals (P60) (Fig. 1E). Interest-
ingly, miR-22 distribution mostly recapitulated the combination
Berenguer et al.
2708 mcb.asm.org Molecular and Cellular Biology
 o
n
 D
ecem
ber 12, 2013 by Red de Bibliotecas del CSIC
http://m
cb.asm
.org/
D
ow
nloaded from
 
of BMP2 and BMP4 expression patterns previously reported by
our group (13).
Expression of miR-22 decreases the cell proliferation rate.
BMPs have been shown to simultaneously repress proliferation
and stimulate terminal neuronal differentiation of CGNPs. Dur-
ing this process, the levels of TIEG-1 and Mash1 increased consid-
erably. Notably, although both transcription factors exhibited a
potent antiproliferative activity, only Mash1 triggered neuronal
differentiation of CGNPs (14, 15). These results indicated that the
effect of BMPs on CGNPs is accomplished through signals that
differentially modulate proliferation and differentiation pro-
cesses. Therefore, we wondered whether miR-22 expression
would alter the proliferation and/or differentiation of CGNPs. So,
we next planned to test the levels of different cell cycle and neuro-
nal differentiation markers in CGNP cultures overexpressing
miR-22. Pilot experiments indicated that the performance of the
commercially available miRNA expression vectors was very poor
in CGNPs. To circumvent this problem, we created a new miRNA
expression vector (pMICRO) based on pCIG (an enhanced GFP
[EGFP]-expressing bicistronic vector) (see Materials and Meth-
ods for vector creation details). We also used pMICRO to express
dec22, a 4decoy sequence designed to neutralize miR-22 activity
(see Materials and Methods for sequence and cloning details). To
study cell proliferation, freshly isolated CGNPs were electropo-
rated with scrambled miR-22 (Scr22) (used as a control) (see Ma-
terials and Methods for the sequence), miR-22, miR-361 (an
miRNA upregulated by DBA but not by BMP2, used as an addi-
tional control), or dec22. Transfected cells were cultured for 48 h
in a medium containing a saturating concentration of Shh (3 g/
ml), and a portion of these cells were treated with BrdU for the last
4 h. Finally, the cultures were fixed and stained with antibodies
against BrdU (Fig. 2A and B). A similar culture was stained with
anti-PCNA, another proliferation marker (Fig. 2C). Interestingly,
the percentage of cells labeled with BrdU or PCNA was signifi-
cantly lower in cultures transfected with miR-22 than in cultures
transfected with empty vector, Scr22, or miR-361. Notably, dec22
consistently reversed the antiproliferative effect induced by miR-
22, and in most cases it significantly elevated the basal prolifera-
tion rate, most likely due to the inhibition of the endogenous
miR-22 (Fig. 2B).
miR-22 knockdown diminishes BMP antiproliferative po-
tency. The good performance shown by the dec22 construct allowed
us to explore the contribution of miR-22 to the antiproliferative effect
developed by BMPs. Thus, control (Scr22) or miR-22-depleted
FIG 1 Experimental design, array results, and expression of miR-22 in CGNPs. (A) Flowchart showing the miRNA array experimental design (Shh, 3 g/ml;
BMP2, 100 ng/ml; and DBA, 1 mM). (B) The panels show the fold change in gene expression relative to the untreated control and the corresponding heat map
of all miRNA species that were changed significantly upon 24-h treatment with DBA or BMP2. The Venn diagram summarizes the common and differentially
regulated miRNAs. (C) miR-22 levels were analyzed by real-time PCR in proliferating CGNP cultures treated for 24 h with 1 mM DBA or 100 ng/ml of BMP2.
Graph bars represent the means standard deviations (SD). (D) Low- and high-magnification images showing in situ hybridizations on 50-m sagittal sections
of P7 mouse cerebella, using either 22-nt Exiqon miRCURY LNA double DIG (5= to 3=)-labeled probes (40 nM scrambled miR as a negative control and 40 nM
miR-22 and 1 nM U6 snRNA as a positive control) or an500-nt DIG-labeled riboprobe directed against MYCN (used as a landmark labeling the outer EGL).
The relative locations of the different cerebellar layers are indicated on the left side of the panel: external germinal layer (EGL), Purkinje cell layer (PC), internal
granular layer (IGL). The bodies of several Purkinje cells in each high-magnification picture are indicated by dotted lines. (E) miR-22 expression in p21 and p60
mouse cerebellum sagittal slices.
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(dec22) CGNPs were cultured for 48 h in a medium containing 3
g/ml of Shh plus different concentrations of BMP2 (0, 10, 50, or
100 ng/ml). The cultures were then pulsed with BrdU for the last 4
h. Remarkably, BrdU counting showed a significant increase in
cell proliferation in dec22-transfected cells at all BMP2 concentra-
tions tested, including the control conditions (no BMP2 added)
(Fig. 2D). This result demonstrates that endogenous miR-22 reg-
ulates cell proliferation in CGNPs and that miR-22 activity is nec-
essary for the proliferation arrest induced by BMP2.
miR-22prolongs cell cycle durationbutdoesnot induceneu-
ronal differentiation of CGNPs. To better understand the effect
of miR-22 on cell cycle progression, we next probed CGNP cul-
tures with antibodies against retinoblastoma PS807 (phosphory-
lation indicates progression through G1 restriction point) (Fig.
3A), Cdc2 PY15 (dephosphorylation is required for G1-to-S and
G2-to-M progression) (Fig. 3B), and histone 3 phosphorylation
(M phase marker) (Fig. 3C). Notably, miR-22 transfection signif-
icantly decreased the number of Rb PS807- and PH3-labeled cells
and increased the number of cells stained with Cdc2 PY15, indi-
cating a reduction in cell cycle progression. In agreement, EGFP-
sorted fluorescence-activated cell sorter (FACS) analysis of similar
CGNP cultures demonstrated an accumulation of cells in G1/G0
and a reduction in G2 and M phases in miR-22-transfected cells
compared to pMICRO (Fig. 3D). Because antiproliferative path-
ways are often associated with apoptosis, we next stained Scr22- or
miR-22-transfected CGNPs with anticaspase 3 to identify apop-
totic cells (Fig. 3E). In both cases, the percentage of apoptotic cells
was very low (0.72% 0.23% and 0.63% 0.41%, respectively)
compared to the positive control, where Scr22-transfected cells
were cultured for the last 12 h with Neurobasal minus B27 sup-
plement (12.03%  0.6%). Since the FACS results could equally
indicate an accumulation of cells in G1 phase or an increase in cell
differentiation (G0), we next wondered whether the cell prolifer-
ation arrest induced by miR-22 was accompanied by an increase in
neuronal differentiation; therefore, we labeled miR-22-trans-
fected CGNPs cultures with Tuj1 (Fig. 3F and H) and HuC/D (Fig.
3G), two neuronal differentiation markers. Cell counting demon-
strated that, in spite of its antiproliferative effect, miR-22 did not
promote neuronal differentiation of CGNPs (Fig. 3F, G, and H).
On the contrary, the percentage of differentiated cells was signif-
icantly increased by BMP2 treatment (100 ng/ml) (Fig. 3F and H).
Altogether, these results indicated that the main miR-22 function
in BMP signaling was related to cell cycle speed control rather than
to cell survival or differentiation. Thus, using a procedure based
on cumulative BrdU labeling, first described by Nowakowski et al.
(24) and recently used to calculate cell cycle duration during ce-
rebral cortex development (25), we calculated the growth fraction
(i.e., the proportion of cells that comprise the proliferating popu-
lation), the length of the cell cycle (Tc), and the length of the
DNA-synthetic phase (Ts). Freshly isolated CGNPs were electro-
porated and cultivated for 24 h in medium containing 3 g/ml of
Shh. At this point, a dose of 50 ng/ml of BrdU was added to the
cultures, and an additional dose of 50 ng/ml was added every 12 h.
The cultures were fixed at the indicated time points and stained
with anti-BrdU. For this experiment, scrambled miR-22 (miR-22-
Scr) rather than empty vector was used as miR-22 control to max-
imize the similarities between the two constructs. The percentage
of cells that incorporated BrdU among the GFP-positive popula-
tion was calculated for each time point and plotted against time as
indicated in reference 24 (Fig. 3I). The tendency lines were gener-
ated for each group with the program GraphPad Prism, and the
equation formula and the R2 coefficient of determination are
FIG 2 Effect of miR-22 overexpression or miR-22 knockdown on CGNP proliferation. The percentage of cells labeled with BrdU or PCNA (X) among
GFP-positive (X/GFP 100) was calculated for each marker. The graphs show the mean  SD of at least 3 independent experiments. The total number of
GFP-positive cells counted for each data point is indicated in each bar. (A to C) Freshly isolated CGNPs were transfected with the indicated constructs and
cultured for 48 h with Shh (3g/ml) (A). Cell proliferation was studied by BrdU incorporation (B) or PCNA staining (C). Constructs: pMICRO (empty vector),
Scr22 (scrambled miR-22), miR-22, miR-361 (miRNA regulated by DBA), dec22 (miR-22 decoy). (D) Cell proliferation was measured by BrdU incorporation
in CGNP cultures transfected with Scr22 or dec22 and cultured for 48 h in medium containing 3 g/ml of Shh plus 0, 50, or 100 ng/ml of BMP2.
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shown in the colored boxes. Notably, the growth fraction, indi-
cated in the plot by the point where the BrdU/GFP index reaches
the “plateau” (dotted line and arrowheads), was very similar in
cells transfected with miR-22-Scr (42.9  0.4) and miR-22 (42.6
 0.1), confirming the absence of prodifferentiation effects of
miR-22. Plotting the data in this way, the slope of the tendency
lines is proportional to the cell cycle speed, and the intersection
between the tendency and plateau lines shows the total cycle du-
ration minus the DNA synthesis phase (Tc Ts) (18.5 h for miR-
22-Scr and 31.9 for miR-22, indicated with arrows on the x axis).
The duration of the S phase (Ts) is obtained from the intersection
between the tendency lines and the y axis. Therefore, total cycle
duration (Tc) can be calculated by adding Ts to Tc Ts. In con-
clusion, miR-22 expression increased the total cycle duration
from 24.9 h to 36.1 h and decreased S-phase extent from 6.4 h to
4.2 h. This result is totally coherent with all the previous data
obtained by FACS analysis or with cell cycle and cell fate markers.
Altogether, these two groups of experiments demonstrate that the
main effect of miR-22 on cell cycle progression consists of a slow-
down of the G1 phase advance.
Max, the obligate partner of N-myc, is a target of miR-22 in
CGNPs.Various lines of evidence support the essential role played
by the transcription factor N-myc in mediating the Shh-depen-
dent proliferation of CGNPs (4–6). In addition, it is also well
established that MYCN is one of the main targets of BMPs in these
cells (14, 15). Interestingly, Max, the obligate partner of N-myc,
was scored as one of the best targets of miR-22 by three different
target prediction programs: miRANDA (www.microrna.org
/microrna/home.do), Targetscan (www.targetscan.org), and Pic-
Tar (http://pictar.mdc-berlin.de).Whereas MYCN mRNA has
FIG 3 Expression of miR-22 increases cell cycle length but does not induce neuronal differentiation of CGNPs. Freshly isolated CGNPs were transfected with the
indicated constructs and cultured for 48 h or longer in Shh (3 g/ml)-containing medium to study different aspects of cell cycle progression. The percentage of
cells labeled with each specific marker (X) among the GFP-positive cells (X/GFP100) was calculated for each marker. The bar graphs show the means SD of
at least 3 independent experiments. The total number of GFP-positive cells counted for each data point is indicated in each bar. Constructs: pMICRO (empty
vector), Scr22 (scrambled miR-22), miR-22, dec22 (miR-22 decoy). (A) Progression through the G1 restriction point was studied by anti-retinoblastoma PS807
labeling. (B) G1-to-S and G2-to-M progression was studied with anti-Cdc2 PY15 antibody. (C) Anti-phospho-histone 3 was used to measure the percentage of
cells in M phase. (D) Representative FACS analysis of GFP/DAPI-stained cells. The percentage of cells in each phase is indicated above each bar. A minimum of
2,500 GFP-positive cells were evaluated in each transfection. (E) Apoptosis was studied by cleaved caspase 3 staining. A B27-deprived culture (Scr-B27) was used
as a positive control for apoptosis. (F to H) Neuronal differentiation of CGNPs was studied at 48 and 72 h by staining with Tuj1 and HuC/D neural markers.
BMP2 treatment at 100 ng/ml was included as a positive control for neuronal differentiation. (I) The effect of miR-22 expression on cell cycle duration was
studied by cumulative BrdU staining. Tendency lines for miR-22 or Scr22 were fitted with the GraphPad Prism statistical program. The growth fraction is given
by the intersection between the plateau lines and the y axis (arrowheads). Total cycle duration (Tc) minus the duration of the S phase (Ts) is given by the
intersection between the tendency lines and the x axis (arrows). The S-phase duration is calculated from the intersection between the tendency lines and the y axis.
The equation formula and the R2 coefficient of determination are shown. The number of cells counted for each data point ranged from 483 to 2,019 with a mean
of 972.
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previously been detected at the outer EGL in P7 mouse cerebellum
(4), little is known about the developmental expression pattern of
Max. Thus, before performing studies to define the functional
relationship between miR-22 and Max, we wanted to first assess
whether the expression pattern of Max is compatible with that of
miR-22 during cerebellum development in vivo (Fig. 4A). We first
confirmed the specificity of the anti-Max antibody by immuno-
precipitation of CGNP lysates and subsequent Western blotting.
This antibody recognized a single band coincident in size with
overexpressed recombinant Max (Fig. 4C). Therefore, we pro-
ceeded to study the distribution of Max protein by immunohisto-
chemistry using sections from 2 different stages of mouse cerebel-
lum development (P4 and P8). We used anticalbindin, a Purkinje
cell maker, and DAPI (4=,6-diamidino-2-phenylindole) to better
delineate the different layers of the cerebellum. Max expression
was observed in the entire EGL at P4 and concentrated to the outer
EGL at P8 (Fig. 4A, enlarged in Fig. 4B). In P8 cerebella, this
expression pattern was coincident with the reported MYCN
mRNA expression (4) and with the layer of highly proliferating
cells of the EGL (labeled with the proliferation marker Ki67) (Fig.
4A’, enlarged in Fig. 4B). Compared to the expression pattern of
MYCN, Max expression was more widely distributed and was also
very abundant in Purkinje cells at all stages and in the differenti-
ated granular cells at the IGL (Fig. 4A and B). Consistent with this,
the Brain Gene Map Database from the Allen Institute (http:
//mouse.brain-map.org) reports very high levels of MAX mRNA
in the cerebellar IGL of adult mice. Thus, in addition to its role as
N-myc partner during proliferation, Max may also exert N-myc-
FIG 4 MAX is a target of miR-22. (A) Max protein expression was studied in sagittal sections of mouse cerebellum at P4 and P8 developmental stages. To better
define Max protein distribution, slices were costained with anticalbindin, a Purkinje cell marker, and the nuclear stain DAPI. (A’) Similar P8 mouse cerebellum
sections were stained with TO-PRO, a DNA dye, and with the proliferation marker Ki67 to expose proliferating cells. (B) Enlargements of the areas boxed in white
in panels A and A’. The locations of the different cerebellar layers are indicated by gray bars above the pictures: PC, Purkinje cell layer; ML, molecular layer; EGL,
external germinal layer. (C) The specificity of the anti-Max antibody was assessed by immunoprecipitation (IP) followed by Western blotting (WB). Anti-Max
antibody immunoprecipitated and blotted a single band in CGNP lysates, which was coincident in molecular weight with recombinant human Max. (D) Max
protein expression levels were measured by IP/WB in cultures transfected with miR-22 or dec22 (miR-22 decoy), and values were actin normalized and
referenced to Scr22 (scrambled miR-22)-transfected controls. Fold change SD from three different experiments is indicated above each lane. (E) The effects
of miR-22 expression onMAXmRNA levels were studied by semiquantitative RT-PCR in CGNP cultures transfected for 48 h. PCR cycles were optimized for each
set of primers to ensure linearity. (F) pLUCMAX (see Materials and Methods for construct details) luciferase activity was studied in CGNPs transfected for 48 h
with either empty vector (pMICRO) or miR-22 or its scrambled control (Scr22). (G) In a similar experiment, the effect of miR-22 expression on pLUCMAX
activity was compared to that on pLUMAX-Scr, a variant of pLUCMAX in which the miR-22 binding site on MAX3=UTR was scrambled. Graph bars represent
the means SD.
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independent functions in differentiated neurons. In fact, it has
been previously reported in both developing brain and the P19
proneural cell line that upon cell cycle exit, Myc is rapidly down-
regulated while Mad is upregulated, forming complexes with
Max to induce differentiation (26, 27). Next, we studied the
capacity of miR-22 to target Max in CGNPs, observing that the
Max protein level was significantly reduced in miR-22-trans-
fected cells compared to cultures transfected with Scr22 or
dec22 (Fig. 4D). In addition, by semiquantitative RT-PCR we
also observed that the Max mRNA level was consistently re-
duced by miR-22 expression (Fig. 3E). Thus, we next per-
formed two sets of experiments to demonstrate the relevance
of the predicted miR-22 binding motif located on the 3=UTR of
MAX mRNA. First, we created an SV40-driven modification of
pGL3 to enable the cloning of the entire MAX mRNA 3=UTR
downstream of the LUC sequence (pLUCMAX) (see Materials
and Methods for vector creation details and mutant se-
quences). Using this tool, we observed that luciferase activity
was significantly reduced by miR-22 expression but not by
scrambled control sequence (Scr22) (Fig. 4F). In the second set
of experiments, we observed that the inhibitory effect of
miR-22 on pLUCMAX luciferase activity was lost in cells trans-
fected with pLUCMAX-Scr, in which the miR-22 binding site
on Max 3=UTR had been scrambled (Fig. 4G). Collectively,
these results demonstrate that Max is a direct target of miR-22
in CGNPs.
miR-22 inhibits N-myc-dependent transcription and prolif-
eration.Although it is well established that N-myc transcriptional
activity requires Max, it remains controversial whether the avail-
ability of Max itself constitutes a mechanism for regulating N-myc
activity. Depending on the cell system used, it has been observed
that an excess of ectopic Max could either enhance or inhibit N-
myc activity. Whereas N-myc appears to interact exclusively with
Max, Max is less selective, as it binds to members of the Mad
family, which function as transcriptional repressors (26, 28).
Therefore, we studied whether miR-22 modulates N-myc-depen-
dent transcriptional activity. Using CGNP cultures growing in a
saturating concentration of Shh (3 g/ml), we cotransfected
miR-22 and N-myc, along with a reporter construct where lucif-
erase was driven either by an artificial 5 E-box or by the natural
human cyclin D2 promoter (Fig. 5A and B). In both cases, the
expression of miR-22 significantly reduced N-myc-dependent
transcription. As other miR-22 targets involving or not MYC ac-
tivity have been reported to modulate cell proliferation (29–32),
we explored to what extent the inhibitory effect of miR-22 on
Shh-induced cell proliferation was due to reduction of Max ex-
pression. Therefore, we analyzed proliferation in CGNPs treated
with Shh and transfected either with miR-22 alone or with miR-22
FIG 5 miR-22 reduces MYC-dependent transcription and proliferation. The bar graphs show the means SD of at least 3 independent experiments. The total
number of cells counted for each data point is indicated in each bar in panels C through G. (A) CGNPs electroporated with a 5 E-box-driven luciferase reporter
vector plus miR-22, MYCN, or their combination were cultured for 24 h with Shh (3g/ml) and for an additional 24 h period without Shh; cells were then lysed,
and luciferase activity was measured. Empty pMICRO vector was used as a control and was also employed to equalize the amount of transfected DNA among
wells. (B) Transfections were performed as described for panel A, but in these experiments the luciferase activity was controlled by the cyclin D2 promoter (which
contains 2 natural E-boxes). (C) CGNPs were transfected with miR-22 or miR-22 plus a nontargetable form of Max and cultured with Shh (3 g/ml).
Proliferation was studied at 48 h by BrdU incorporation. (D, E) The effect of miR-22 expression on cell proliferation was assessed in two different human
neuroblastoma cell lines, SK-BE (bearing a MYCN amplification) and SH-SY-5Y (no MYCN amplification). Proliferation of cells was estimated by BrdU
incorporation 48 h after transfection. (F, G) In a similar experiment, the effect of miR-22 expression was evaluated in two cell lines for which proliferation has
been reported to depend on MYC activity, C17-2, a murine neuroectodermal cell line created through v-myc transformation, and D283, a human medulloblas-
toma cell line with high levels of Myc but without MYC or MYCN amplifications.
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plus a vector containing a nontargetable form of Max (Fig. 5C).
Although proliferation was significantly rescued by cotransfection
of Max, it did not reach the levels of control cells, suggesting that
our transfection conditions failed to achieve the optimal N-myc/
Max ratio needed for proliferation or, alternatively, that other
targets of miR-22 contribute additionally to the inhibition of Shh-
mediated proliferation. As mentioned above, N-myc-dependent
transcription plays a key role in the physiologic expansion of dif-
ferent neuronal populations, including CGNPs. In addition,
genomic amplifications of MYCN are found in a subset of neuro-
blastomas with a particularly poor prognosis. Thus, we postulated
that the expression of miR-22 in neuroblastoma-derived cell lines
(33) would inhibit proliferation, similar to our observations in
CGNPs. Interestingly, ectopic expression of miR-22 significantly
reduced proliferation in the SK-BE(2C) cell line, where MYCN is
highly amplified, but not in SH-SY-5Y cells, where MYCN gene
expression is normal (Fig. 5D and E). To further substantiate the
inhibitory effects of miR-22 on MYCN-dependent proliferation,
we tested miR-22 expression in two unrelated cell lines in which
MYC proteins have a key role in proliferation. Thus, cell prolifer-
ation was reduced by ectopic expression of miR-22 in both C17-2,
a murine neuroectodermal cell line generated through v-myc
transformation, and D283, a human medulloblastoma cell line
with high levels of Myc but withoutMYC orMYCN amplifications
(34, 35) (Fig. 5F and G).
DISCUSSION
BMP2 and PKA activation downregulate the miR-17-92 cluster
expression. The miR-17-92 cluster, also called Oncomir-1, was
among the first miRNAs to be validated as showing oncogenic
potential and was shown to collaborate with Myc in B cell lym-
phoma formation (36). Since then, several lines of evidence have
suggested a positive functional relationship between Shh pathway
and miR-17-92 expression during physiologic and pathological
cerebellum development. Thus, the miR-17-92 cluster was found
to be expressed in the developing mouse cerebellum and in pro-
liferating CGNPs but not in postmitotic differentiated neurons
(37). In addition, the miR-17-92 cluster level was observed to be
very high in mouse and human medulloblastomas with an aber-
rantly activated Shh pathway. Moreover, medulloblastoma pen-
etrance in immunocompromised mice orthotopically trans-
planted with CGNPs purified from P6 Patch/; Ink4c/ mice
was about 30% but increased to 100% when the CGNPs were
transduced with the miR-17-92 cluster before transplantation
(37). On the contrary, no medulloblastomas were formed when
the CGNPs were obtained from Ink4c/; p53/ mice. There-
fore, considering that the miR-17-92 cluster has been shown to be
a direct target of Myc (38) and that the Shh pathway increased
MYCN expression in CGNPs (4) and in medulloblastomas (39), it
is logical to think that Shh-dependent regulation of miR-17-92
expression in CGNPs and medulloblastoma is mediated by N-
myc. Previous reports demonstrated that BMP2 treatment (14,
16) and PKA activation (40) decreased N-myc levels in P6 CGNPs.
In addition, in the present work we show a downregulation of the
miR-17-92 cluster expression induced by BMP2 and DBA (PKA
activation). It therefore suggests that Shh and BMP pathways con-
verge over NMYC to regulate miR-17-92 cluster expression. In
agreement, we previously reported a significant decrease of
MYCN mRNA (at 12 h) and N-myc protein (at 24 h) induced by
BMP2 treatment (14). On the contrary, however, Zhao et al. (16)
did not find differences in N-myc expression until 72 h of BMP
treatment (but no time points between 24 and 72 h were studied),
suggesting that BMP2 regulation of miR-17-92 could occur prior
to N-myc variation. In any case, a probable explanation for this
apparent discrepancy may be found in the way the P6 CGNPs
cultures are prepared in the different laboratories. In our group,
we always leave the culture to recover for the first 24 h (in Shh at 3
g/ml) before starting any experiment, for we observed that either
due to the aggressiveness of the disaggregation treatment itself or
due to inherited inhibitory signals, the responsiveness of CGNPs
during this period is diminished.
miR-22operates downstreamfromBMPscontrolling cell cy-
cle length but does not induce differentiation. miRNAs are
emerging as master regulators of development that control cellu-
lar proliferation and differentiation and have therefore also been
linked to cancer (41). Previously, we reported that BMPs induce a
rapid exit from the cell cycle and thereby induce the differentia-
tion of CGNPs in vivo and in culture (13). Here, using the same
cellular model, we have observed a marked upregulation of
miR-22 expression in response to BMP2 (Fig. 1B and C), coinci-
dent with cell cycle arrest and induction of the differentiation
process. Whether the BMPs are the only extracellular signals that
regulate mirR-22 expression in cerebellum remains to be deter-
mined, since we cannot yet exclude the possibility that other fac-
tors that promote the differentiation of CGNPs also upregulate
miR-22 expression. The fact that miR-22 expression in CGNP
cultures was also increased by PKA activation suggests that
miR-22 may be a common element of different antiproliferative/
prodifferentiation pathways. In 2009, Roussel’s group performed
a very extensive study in which the miRNomes from wild-type
mouse cerebella (P6, P30, and purified CGNPs) were compared to
cerebella obtained from different mouse models of medulloblas-
toma and to medulloblastomas from these models. Although
some of the miRNAs that were increased in P30 cerebellum com-
pared to P6 were also increased in our DBA treatment (miR300
and miR128), no significant differences in miR-22 levels were re-
ported (37), suggesting that compared to other miRNAs, miR-22
is not specifically linked to the terminal differentiation status. In
agreement with Uziel et al., our IH study shows that miR-22 is
expressed at the inner EGL and IGL of P7 mouse cerebellum,
being still abundant at the IGL of P21 but almost undetectable in
adult mice (P60) (Fig. 1E), altogether suggesting a role during the
differentiation process but not in maintaining the differenti-
ated condition. Similar to neuronal progenitors, cell cycle ar-
rest is normally accompanied by terminal differentiation in
many other cell types as hematopoietic cells or myocytes. In-
terestingly, miR-22 was previously reported to be induced by
tetradecanoyl phorbol acetate (TPA) treatment of the hemato-
poietic HL-60 cell line, which triggers their differentiation
(42), and was in the differentiation-associated miRNA group in
myoblast-myotube differentiation; as observed in CGNPs,
miR-22 reduced myoblast proliferation (29). Additionally,
miR-22 was identified as a signature miRNA for erythrocyte
maturation (43). However, our results clearly demonstrate that
at least in CGNPs, miR-22 slows down the cell cycle progres-
sion but does not induce neuronal differentiation, indicating
that the reported presence of miR-22 in various differentiating
cell types does not necessarily imply a direct role of miR-22 in
the differentiation process. Moreover, miR-22 has also been
demonstrated to have a potent antiproliferative effect in differ-
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ent cancer cell lines (30) and to induce senescence in fibroblasts
(32). Thus, given that compounds that promote differentiation
or senescence exert their effects primarily on the cell cycle,
miR-22 may reflect a common antiproliferative element work-
ing in different cellular processes whereby a slowdown in the
cell cycle is required. Similarly, TIEG-1 and Mash1 are both
antiproliferative transcription factors reported to increase dur-
ing BMP-induced neuronal differentiation of CGNPs, and al-
though in overexpression experiments only Mash1 induced
neuronal differentiation, the dose of BMP2 required to induce
neural differentiation was 100 times lower in TIEG-1-overex-
pressing cells (14, 15), suggesting that proliferation-arrested
neural progenitors were more prone to differentiate. Now that
we have observed that the miR-22 effect is very similar to that
carried out by TIEG-1, it will be interesting to assess whether
these two molecules work in parallel or alternatively in a con-
secutive manner. Coherent with the effect of miR-22 on pro-
liferation, we observed that expression of miR-22 decreases
Max levels and MYCN-dependent signaling in primary cultures
of CGNPs, and these data are in agreement with a recent report
(30) identifying Max as a target of miR-22 in the A549 lung
carcinoma cell line. However, the fact that the antiproliferative
effect of miR-22 was only partially rescued by restoring Max
expression strongly suggests that miR-22, similar to other
known miRNAs, develops its activity through a multitarget
mechanism. Indeed, MYCBP, another regulator of MYC sig-
naling, is also targeted by miR-22 (31). Thus, more studies will
be required to reveal the individual contribution of each
miR-22 target on the cell cycle.
Possible role ofmiR-22 in regulating neoplastic growth. The
increasing information regarding miRNA target networks has
begun to reveal a new level of complexity in cell physiology.
These networks function together with transcription factors to
more precisely regulate different cellular process. Thus, onco-
genic factors like MYC proteins initiate both transcription (44)
and miRNA cascades (45) to control a range of biological ac-
tivities, including proliferation, differentiation, and cellular
energy production. Moreover, a bidirectional cross talk be-
tween these two types of regulators most likely exists, whereby
oncogenes regulate the expression of specific miRNAs, and in
turn, certain groups of miRNAs regulate parameters of onco-
gene signaling. Although it was shown initially that Myc onco-
genic activity was highly dependent on the upregulation of a
protumorigenic group of miRNAs known as the miR-17-92
cluster (46), a more recent study has demonstrated that Myc
also represses the expression of an important group of antipro-
liferative/differentiation-related miRNAs; ectopic expression
of these miRNAs diminishes the tumorigenic potential of Myc-
induced lymphoma cells (47). Notably, miR-22 was one of the
miRNAs whose expression decreased most significantly in re-
sponse to MYC activation (47). On the other hand, it has been
shown that components of the MYC signaling complex, includ-
ing MYCBP, a positive regulator of Myc (31), or the Myc part-
ner Max (30) are direct targets of miR-22. Recombinant ex-
pression of miR-22 significantly reduces Myc-dependent
signaling and tumorigenic effects in different cell types (30,
31). Thus, a reciprocal negative autoregulatory loop between
MYC signaling and miRNAs such as miR-22 seems to exist.
Compared to proto-oncogenes such as Ras, where oncogenicity
is usually caused by mutations in the protein, MYC proteins
very rarely bear mutations, and thus, their oncogenic potential
depends rather on expression levels. Deregulation of MYC ex-
pression due to mechanisms including retroviral insertion,
chromosomal translocation, and gene amplification is known
to be the cause of various neoplastic processes (7). Therefore, it
is plausible that loss of even a single element controlling MYC
levels would be sufficient to initiate or maintain neoplastic
growth. The miR-22 locus in humans is situated at position
1,220,571.1,220,655 (NCBI Genome Browser or Sanger
miRNA database numbering) in the 17p13.3 band. Interest-
ingly, loss of the 17p region is a rather common chromosomal
aberration in different tumor types. In medulloblastomas, a
malignancy arising from cerebellar cell precursors, loss of 17p
is found in up to 50% of the tumors and is considered an
indicator of a poor prognosis (48–50), and although 17p loss is
more frequent in medulloblastoma groups 3 (45%) and 4
(60%), up to 20% of Shh group medulloblastomas present
deletions in 17p (51), converting it into a common feature
among different medulloblastoma types. However, the fact that
tp53 gene is located in the 17p13.1 band led to the hypothesis
that tumorigenicity associated with 17p loss was due mostly to
a lack of p53 expression. Nevertheless, it was observed that in a
proportion of medulloblastomas the deletion was limited to
the 17p13.3 band and tp53 was not mutated (52–54). Thus, it
seems very probable that other tumor suppressors are lost in
17p deletions. Consistent with this, several other genes were
proposed to be responsible for the tumorigenic effect of 17p
deletions (55). In agreement, a recent work has demonstrated
that miR33b, a statin-regulated microRNA located at 17p11.2,
targets MYC and regulating c-Myc-dependent medulloblas-
toma proliferation (35). In any case, additional studies will be
required to define the precise contributions of miR-22 loss to
neoplastic growth.
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